Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

Community Prescribing and Resistant Streptococcus pneumoniae

Galia Barkai*, David Greenberg*, Noga Givon-Lavi*, Eli Dreifuss†, Daniel Vardy†, and Ron Dagan*Comments to Author 
Author affiliations: *Soroka University Medical Center and Ben-Gurion University of the Negev, Beer-Sheva, Israel; †Israel General Health Insurance Plan, Beer-Sheva, Israel

Main Article

Figure 1

Antimicrobial drug prescription rates for Bedouin and Jewish children <5 years of age in southern Israel from 1998 through 2003. Amoxi, amoxicillin; Amoxi-clav, amoxicillin-clavulanate; Pen, phenoxymethyl penicillin; Azithro, azithromycin; Ceph, cephalosporins (cefazolin, cefaclor, cephalexin monohydrate, and cefuroxime-axetil); Ery, erythromycin.

Figure 1. . Antimicrobial drug prescription rates for Bedouin and Jewish children <5 years of age in southern Israel from 1998 through 2003. Amoxi, amoxicillin; Amoxi-clav, amoxicillin-clavulanate; Pen, phenoxymethyl penicillin; Azithro, azithromycin; Ceph, cephalosporins (cefazolin, cefaclor, cephalexin monohydrate, and cefuroxime-axetil); Ery, erythromycin.

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external